I-Mab entered into agreement to acquire 100% ownership of Bridge Health Biotech

I-Mab (IMAB) announced that it entered into a definitive agreement to acquire 100% ownership of Bridge Health Biotech. The transaction provides I-Mab with the rights to bispecific and multi-specific applications, based on the Claudin 18.2 parental antibody used in the Company’s CLDN18.2 x 4-1BB bispecific antibody, givastomig. Under the terms of the agreement, I-Mab will pay Bridge Health shareholders an upfront payment of $1.8 million and non-contingent payments of $1.2 million through 2027. In addition, Bridge Health shareholders may receive future milestone payments of up to $3.875 million, subject to the achievement of certain development and regulatory milestones. The transaction is expected to close in Q3 of 2025.